Use of monoclonal antibodies in patients with multiple sclerosis in the practice of a neurologist

• Main Author: N. Yu. Lashch
• Format: Article
• Language: Russian
• Published: Remedium Group LLC 2020-03-01
• Series: Медицинский совет
• Subjects: multiple sclerosis; monoclonal antibody; dmt; highly active multiple sclerosis; safety; efficiency; alemtusumab; immunomodulatory therapy
• Online Access: https://www.med-sovet.pro/jour/article/view/5523
• ISSN: 2079-701X; 2658-5790

Multiple sclerosis (MS) ranks first for prevalence among diseases affecting the CNS white matter with 2.5 million cases estimated globally. InRussia, the number of cases is about 200 thousand. MS in most cases has a wavy course (periods of exacerbations and remissions), over time the progression of disease worses the quality of life of patients. The “gold standard” at the beginning of MS is first-line drugs disease-modifying therapies (DMT). If they are ineffective, it is necessary to strengthen the effect on the immune processes and the patient is prescribed second-line drugs (escalation of therapy). There is a method of induction therapy, when high activity of MS is recommended to start with drugs that have a strong immunosuppressive effect with a possible subsequent transition to soft supportive treatment. In patients with frequent exacerbations and signs of radiological activity of the disease, according to magnetic resonance imaging (MRI) of the brain and spinal cord, monoclonal antibody preparations are effectively used. Except of escalation and induction, it is also used the method of immune system reconstruction, which leads to a decrease in autoagression in MS. This article discusses a clinical case of using a drug of monoclonal antibodies that selectively bind to CD 52 on the surface of lymphocytes. The issues of efficacy and safety of alemtuzumab therapy in patients with MS are considered.